Nymox Pharmaceutical Corporation (NASDAQ:NYMX) recently announced that it shall take the analysis of its prostate enlargement (BPH) drug, NX-1207 to the next level. Nymox said that it will undertake U.S. Phase 3 studies analysis further, by including the long-term data from its studies of NX02-0018 and NX02-0017. The details about the new Phase 3 study shall be announced by the company in second or third quarter of this year.
The NX02-0018 and NX02-0017 studies
The aforesaid key U.S. studies were started by the company in the year 2009. Thereafter, it completed enrolment of 499 randomized patients in NX02-0017 study in the year 2012. The enrolment of 498 patients was done in NX02-0018 in 2013.
973 of these patients were given either the lone saline vehicle or NX-1207 2.5 mg. After a year of the treatment, there was no improvement in terms of the statistics data, which would have reinforced the efficiency of this treatment regarding symptom score or control. However, the safety concerns of NX-1207 proved to be satisfactory.
BPH long-term management through NX-1207 expected
The CEO of Nymox Pharmaceutical Corporation, Dr. Paul Averback said that even if the top-line results did not provide the expected results, but the company shall continue to strive in the potential of NX-1207 in long-term BPH management. At the same time, the company is also trying to capture the protocol data from the two studies. This is done so that the enduring results in patients suffering from BPH from over 5 years after NX-1207 2.5 mg vs placebo treatment can be studied.
At present, NX-1207 has reached its last stage as far as the development is concerned. The treatment will prove to lower down the grade of localized kind of prostate cancer. Last year, Nymox Pharmaceutical Corporation (NASDAQ:NYMX) had revealed its efficiency results for 8 months durations. It reported that there was statistically significant reduction in the progression of cancer among those patients who were injected with NX-1207. This improvement with the treatment was better in comparison to the standard of care.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: